Oxymetazoline hydrochloride cream for facial erythema associated with rosacea

被引:24
作者
Patel, Nupur U. [1 ]
Shukla, Shweta [1 ]
Zaki, Jessica [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA
关键词
Erythema; FDA approval oxymetazoline hydrochloride; rhofade; rosacea; topical medication; 2 PIVOTAL TRIALS; 1.0-PERCENT; EFFICACY; SAFETY; DIAGNOSIS; CONSENSUS; IMPACT;
D O I
10.1080/17512433.2017.1370370
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face. The symptom of persistent erythema can be particularly frustrating for both patients and physicians as it is difficult to treat.Areas covered: Current treatment options for the treatment of rosacea include metronidazole, azelaic acid, sodium sulfacetamide-sulfur, and brimonidine. Until recently, brimonidine gel was the only option approved specifically for the treatment of facial erythema. However, oxymetazoline hydrochloride 1% cream is a newly FDA approved topical medication for adult rosacea patients. A primarily alpha-1a agonist, oxymetazoline hydrochloride (HCl) is thought to diminish erythema through vasoconstriction. Our paper seeks to evaluate evidence for topical oxymetazoline HCl with respect to its efficacy and safety for its approved indication of treating the persistent erythema associated with rosacea.Expert commentary: While assessment of available clinical trial data indicates that the medication is as effective as other available treatment for controlling rosacea-associated erythema with minimal risk of adverse effects, studies of long-term duration and direct comparison will be necessary to establish its place in treatment guidelines and clinical practice. As further evidence becomes available, the real-world clinical potential of topical oxymetazoline cream will become clearer.
引用
收藏
页码:1049 / 1054
页数:6
相关论文
共 33 条
[11]   Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group [J].
Elewski, B. E. ;
Draelos, Z. ;
Dreno, B. ;
Jansen, T. ;
Layton, A. ;
Picardo, M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (02) :188-200
[12]  
Ferrusi IL, 2017, J AM ACAD DERMATOL, V76, pAB190
[13]  
Generali Joyce A, 2013, Hosp Pharm, V48, P558, DOI 10.1310/hpj4807-558
[14]  
Gibson LE, 2004, MAYO CLIN PROC, V79, P1192
[15]   Comorbidity of rosacea and depression: An analysis of the national ambulatory medical care survey and National Hospital Ambulatory Care Survey - outpatient department data collected by the US National Center for Health Statistics from 1995 to 2002 [J].
Gupta, MA ;
Gupta, AK ;
Chen, SJ ;
Johnson, AM .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (06) :1176-1181
[16]   Feelings of stigmatization in patients with rosacea [J].
Halioua, B. ;
Cribier, B. ;
Frey, M. ;
Tan, J. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) :163-168
[17]  
Huynh TT, 2013, AM HEALTH DRUG BENEF, V6, P348
[18]   Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline [J].
Kim, Jae-Hong ;
Oh, Yoon Seok ;
Ji, Jae Hong ;
Bak, Hana ;
Ahn, Sung Ku .
JOURNAL OF DERMATOLOGY, 2011, 38 (05) :511-513
[19]  
Kircik LH, 2017, J AM ACAD DERMATOL, V76, pAB115
[20]  
Kuo S, 2015, CUTIS, V95, P37